There was no significant difference in terms of major adverse cardiovascular events
in patients with occluded and non-occluded coronary arteries (Hazard Ratio: 0.
Ranolazine has not been determined to be safe or efficacious as a treatment to reduce major adverse cardiovascular events
in patients who have undergone PCI.
The cohort study of 5,964 patients with hidradenitis suppurativa showed that, after adjustment for confounders such as age, sex, smoking, and other comorbidities, hidradenitis suppurativa was associated with a 57% greater risk of myocardial infarction, a 33% greater risk of ischemic stroke, a 53% increase in major adverse cardiovascular events
, and a 35% increase in all-cause mortality over a mean 7.
Researchers found that among women, cangrelor reduced the odds of major adverse cardiovascular events
by 35 percent and reduced the odds of stent thrombosis (clot in a stent) by 61 percent when compared to standard therapy.
Outcomes include choice of medication, adherence, and major adverse cardiovascular events
Mills and his colleagues then considered two separate definitions of cardiovascular events: the first was any such event, including minor occurrences such as palpitations, and the second was only major adverse cardiovascular events
as defined by the Food and Drug Administration, which is "considered to be a more stringent definition of important patient outcomes.
Diabetic patients whose co-morbid heart disease is treated with percutaneous coronary intervention have an increased risk of repeat procedures and other major adverse cardiovascular events
," explained Prof.
The primary objective was to evaluate the occurrence of major adverse cardiovascular events
(MACE) in overweight and obese adults with cardiovascular risk factors receiving Contrave.
The primary efficacy endpoint of the study was the composite measure of adjudicated major adverse cardiovascular events
, comprising the time to first occurrence of cardiovascular death, myocardial infarction, or severe recurrent ischemia requiring urgent coronary artery revascularization.
The overall rate of the primary end point, a composite of all major adverse cardiovascular events
, was 2.
While the clinical endpoint of the trial is the ability to treat the patient without the incidence of major adverse cardiovascular events
(MACE), the trial will be closely monitoring the radiation exposure of interventional cardiologist while using the CorPath technology compared to the radiation exposure if the operator was performing the procedure at the table.
The co-primary endpoints for both the studies are time taken for the first occurrence of major adverse cardiovascular events
(MACE) and mean change in haemoglobin levels between the baseline and efficacy period.